Goals

The New York State Ending the Epidemic (ETE) initiative presents strategies from the ETE Task Force to decrease HIV prevalence and end the AIDS epidemic in New York State. The third pillar of the 3-pillar ETE plan is facilitating access to PrEP as a proven strategy to prevent HIV acquisition among individuals at risk. Its inclusion as a pillar of this initiative emphasizes the safety and effectiveness of PrEP as a method to prevent HIV infection. This guideline was developed by the Medical Care Criteria Committee of the NYSDOH AI Clinical Guidelines Program to provide clinicians throughout New York State with the recommendations needed to successfully start and continue patients on PrEP.

In support of the ETE initiative and to reduce new HIV infections in New York State, the goals of this guideline are to:

• Increase awareness and knowledge of PrEP efficacy among clinicians in New York State.
• Assist clinicians in identifying candidates for PrEP and increasing awareness of, access to, and uptake of PrEP among individuals in New York State at risk of acquiring HIV through sexual and drug use exposures.
• Discuss the barriers to PrEP access and encourage clinicians to assist PrEP candidates in reducing or eliminating these barriers.
• Provide clinicians with the information needed to help a PrEP candidate make the best choice regarding oral versus injectable PrEP and daily versus on-demand PrEP.
• Provide clinicians with evidence-based recommendations for PrEP initiation, management, monitoring, and discontinuation.

Note on “experienced” and “expert” HIV care providers: Throughout this guideline, when reference is made to “experienced HIV care provider” or “expert HIV care provider,” those terms are referring to the following 2017 NYSDOH AI definitions:

• Experienced HIV care provider: Practitioners who have been accorded HIV Experienced Provider status by the American Academy of HIV Medicine or have met the HIV Medicine Association’s definition of an experienced provider are eligible for designation as an HIV Experienced Provider in New York State. Nurse practitioners and licensed midwives who provide clinical care to individuals with HIV in collaboration with a physician may be considered HIV Experienced Providers as long as all other practice agreements are met (8 NYCRR 79-5:1; 10 NYCRR 85.36; 8 NYCRR 139-6900). Physician assistants who provide clinical care to individuals with HIV under the supervision of an HIV Specialist physician may also be considered HIV Experienced Providers (10 NYCRR 94.2)
• Expert HIV care provider: A provider with extensive experience in the management of complex patients with HIV.

PrEP Access and Coverage

U.S. Food and Drug Administration (FDA)-approved agents for PrEP: Tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg in a fixed-dose tablet (TDF/FTC; brand name Truvada) is approved by the FDA for use as PrEP as part of a comprehensive HIV prevention strategy for individuals at risk of acquiring HIV. Multiple randomized, placebo-controlled clinical trials have demonstrated the efficacy of TDF/FTC as PrEP for preventing HIV infection in all populations.

Tenofovir alafenamide 25 mg/emtricitabine 200 mg in a fixed-dose tablet (TAF/FTC; brand name Descovy) was found to be noninferior to TDF/FTC in a study of men who have sex with men (MSM) and a small number of transgender women who have sex with men [Mayer, et al. 2020]. TAF/FTC was approved by the FDA in October 2019 for HIV prevention through sexual exposure in those groups; it has not yet been approved for prevention of HIV through receptive vaginal exposure [FDA(a) 2019].

Long-acting injectable cabotegravir (CAB LA; brand name Apretude), an integrase strand transfer inhibitor given as a bimonthly injection after a 5-week oral CAB (brand name Vocabria) lead-in and after 2 initial injections given 4 weeks apart, was statistically superior to oral TDF/FTC as PrEP in MSM and transgender women [Landovitz, et al. 2021] and in cisgender women [Delany-Moretlwe, et al. 2022] CAB LA was approved by the FDA in December 2021 for prevention of HIV via all sexual exposures [FDA(b) 2021].

PrEP uptake: Although new HIV infections and diagnoses have steadily declined in New York State, these decreases have not been uniform across all groups. MSM and people of color, particularly young MSM and women of color, continue to be overrepresented among those newly infected and diagnosed with HIV [NYSDOH 2018]. Computer simulation modeling suggests that increased PrEP uptake will be the single largest contributor to further reductions in new HIV infections and key to ending the HIV epidemic in New York State [NYSDOH 2018]. However, data indicate that people of color, women, and individuals accessing Medicaid—3 groups overrepresented among people with HIV—are accessing PrEP at lower levels than other groups in whom the disease burden is high [ETE Dashboard 2020]. For example, in 2020, 19.4% of new HIV diagnoses in New York State were in women, but just 8.1% of all individuals who accessed PrEP in New York State were women. Nationally, although White MSM account for 30% of new HIV infections, nearly 75% of prescriptions for PrEP in the United States have gone to White MSM, illustrating the need to improve outreach to other communities affected by HIV [Townes, et al. 2021; Jenness, et al. 2019; Goedel, et al. 2018; Goldstein, et al. 2018].

Barriers to PrEP access and use: The NYSDOH AI recognizes that a comprehensive approach is necessary to ensure that individuals who will most benefit from the use of PrEP have access to it and that their care is managed effectively while they are taking PrEP. This guideline addresses some structural barriers to PrEP care by advocating for individualization and flexibility in care-delivery models, including monitoring schedules and dosing options.

Barriers to PrEP access include:

• Suboptimal awareness or acceptance of PrEP among some individuals at risk for acquiring HIV and their care providers [Townes, et al. 2021; Bazzi, et al. 2018; Mayer, et al. 2018; Rael, et al. 2018; Bien, et al. 2017; Blackstock, et al. 2017; King, et al. 2014]
• Lack of retention in PrEP care due to individual and structural barriers [D'Angelo, et al. 2021; Serota, et al. 2020; Chan, et al. 2016]
• Stigma, which may keep people who would benefit from PrEP from using it
• Disparities in access to PrEP among populations at high risk of HIV acquisition, including MSM of color, transgender women, Black women, and people who inject drugs [Biello, et al. 2018; CDC(a) 2018; Garnett, et al. 2018; Morgan, et al. 2018; Sullivan, et al. 2018; Lancki, et al. 2018; Page, et al. 2017; Philbin, et al. 2016; Sevelius, et al. 2016; King, et al. 2014]. Emerging evidence suggests that transgender MSM are also at high risk for HIV acquisition [Pitasi, et al. 2019; Scheim, et al. 2017] and are a population for whom PrEP outreach and access are needed.

The availability of injectable PrEP creates unique opportunities and potential challenges for systems to incorporate this option. Populations at the highest risk of acquiring HIV should be prioritized for PrEP outreach and access to ensure they are aware of PrEP and its benefits. PrEP programs will have to develop systems and protocols to make injectable PrEP available.

It is also crucial to address barriers and expand access to PrEP by increasing the number of medical care providers who are aware of and willing to prescribe PrEP. Care providers need to examine any unconscious biases that may influence their willingness to offer PrEP to patients [Calabrese, et al. 2018; Edelman, et al. 2017; Calabrese, et al. 2014], avoid making assumptions about sexual practices, and develop comfort and facility in obtaining routine sexual histories and asking about injection drug use practices to identify potential PrEP candidates. Regardless of disclosed risk, if a patient asks for PrEP and it is not medically contraindicated, they should be offered a prescription and appropriate follow-up.

Coverage under the Affordable Care Act (ACA): In August 2023, the U.S. Preventive Services Task Force (USPSTF) published an updated grade A recommendation stating that clinicians should “prescribe preexposure prophylaxis using effective antiretroviral therapy to persons at increased risk of HIV acquisition to decrease the risk of acquiring HIV” [USPSTF 2023]. The updated USPSTF recommendation statement also includes a review of the evidence on newer HIV PrEP medications, including oral TAF/FTC and long-acting CAB, in addition to oral TDF/FTC. This federal recommendation recognizes PrEP as a preventive service to be covered under the ACA, a significant step toward increasing access to PrEP, and further affirms PrEP as a highly effective HIV prevention strategy that clinicians can and should provide to their patients.

Coverage in New York State: In July 2019, the New York State Department of Financial Services issued a Circular Letter instructing New York State insurers to cover PrEP without cost-sharing, including copays and deductibles, which have been a major financial barrier for many consumers.

PrEP Candidates

PrEP is part of a comprehensive HIV prevention plan and should be offered to individuals, including adolescents who meet the prescribing criteria, who are assessed or who self-identify as being at increased risk of acquiring HIV through sexual or injection drug exposure.

Box 1, below, shows candidates who should be offered PrEP (e.g., those at risk of acquiring HIV through rectal, genital, or blood exposures, and those who request PrEP) and factors that do not disqualify candidates from PrEP.

Men who have sex with men (MSM): Studies have demonstrated that TDF/FTC as PrEP is highly effective in MSM [Mayer, et al. 2020; McCormack, et al. 2016; Molina, et al. 2015; Grant, et al. 2014; Grant, et al. 2010]. Although initial data from the iPrEx trial demonstrated only a 44% reduction in the rate of HIV acquisition, there was a 92% reduction in sexual transmission when tenofovir was detectable in the blood. No seroconversions occurred in individuals with therapeutic plasma concentrations of TDF/FTC [Grant, et al. 2010]. In the PROUD study TDF/FTC as PrEP had an overall efficacy rate of 86%, and there were no HIV infections in participants who took TDF/FTC as prescribed [McCormack, et al. 2016]. Based on intracellular concentrations of tenofovir diphosphate, HIV risk-reduction efficacy in the iPrEX study was estimated to be 99% with 7 doses per week, 96% with 4 doses per week, and 76% with 2 doses per week [Anderson, et al. 2012].

The DISCOVER study showed both TDF/FTC and TAF/FTC to be highly effective in reducing the risk of HIV infection in MSM, with a combined total of 22 participants with new HIV infections in 8,756 person-years of follow-up; all except 2 were either infected at baseline or had low tenofovir plasma concentrations at the time of infection [Mayer, et al. 2020]. In the HPTN 083 study, both TDF/FTC and long-acting injectable cabotegravir (CAB LA; brand name Apretude) prevented HIV in MSM and transgender women. However, CAB LA was statistically superior, with 14 incident infections among participants receiving the regimen, compared with 41 incident infections among participants taking TDF/FTC during the blinded phase of the study, mostly driven by adherence and low tenofovir levels in individuals seroconverting on TDF/FTC [Landovitz, et al. 2022; Landovitz, et al. 2021].

Transgender women: In the iPrEx study, TDF/FTC as PrEP was effective in transgender women who adhered to the regimen. In a subanalysis of transgender women in the iPrEx study, there was no difference in rates of HIV infection between the PrEP and placebo groups; however, none of the transgender women who seroconverted had detectable tenofovir levels, and there were no HIV infections in those who had adequate tenofovir levels [Deutsch, et al. 2015]. Subsequent analysis has shown significant differences in the baseline characteristics between MSM and transgender women in the iPrEX study [Mehrotra, et al. 2019].

Multiple studies have shown that TDF/FTC does not alter estrogen levels [Grant, et al. 2021; Shieh, et al. 2019; Hiransuthikul, et al. 2019]. Small studies have raised the possibility that estrogen lowers tenofovir levels by approximately 12% in the plasma of transgender women compared with cisgender men or lowers levels of active metabolite in rectal tissues [Cottrell, et al. 2019; Shieh, et al. 2019], although the significance of this difference is unclear. In the larger iBrEATHe study, which used directly observed daily oral TDF/FTC as PrEP for 4 weeks in transgender women on consistent hormone therapy, differences in tenofovir levels measured by dried blood spots did not meet statistical significance [Grant, et al. 2021]. In the ImPrEPT study among transgender individuals taking TDF/FTC as PrEP, no interactions between hormone therapy and PrEP were reported [Blumenthal, et al. 2022]. It is possible that higher levels of adherence are needed among transgender women using estrogens and taking TDF/FTC for PrEP than among cisgender men, but levels achieved with daily dosing will confer protection from TDF/FTC as PrEP.

TAF/FTC was effective in transgender women in the DISCOVER study, but transgender women made up only 1% of the study population [Mayer, et al. 2020]. There are no formal pharmacokinetic studies of the effects of estrogen at doses used for gender-affirming care on TAF levels, but intracellular PBMC concentrations of tenofovir diphosphate were similar between transgender women taking gender-affirming hormone therapy and MSM in the DISCOVER study [Cespedes, et al. 2020]. There are also no pharmacokinetic studies of the effects of estrogen at doses used for gender-affirming therapy on CAB LA levels, but in the HPTN 083 study, transgender women made up 12.5% of the study population, and CAB LA was effective across all subpopulations. Additionally, oral CAB pharmacokinetics were not significantly altered by low-dose hormones used for oral contraceptives in the HPTN 077 study [Blair, et al. 2020].

Transgender men: Data are lacking regarding the efficacy of TDF/FTC, TAF/FTC, and CAB LA as PrEP for transgender men who have sex with either cisgender men or transgender women, despite the increased risk of HIV acquisition in this population [Pitasi, et al. 2019; Scheim, et al. 2017]. In the iBrEATHe study, TDF/FTC did not lower testosterone levels in transgender men compared with controls, and testosterone did not lower tenofovir levels in transgender men compared with cisgender men [Grant, et al. 2021]. Tenofovir levels were lower in transgender men than in cisgender women; however, levels were still in a range consistent with effective PrEP with TDF/FTC in clinical trials. There are no data yet on whether testosterone therapy affects CAB levels. However, there is no specific reason to believe that CAB LA will be less effective for vaginal or anal exposures in preventing HIV infection in this population.

Cisgender men and women: Studies have demonstrated that TDF/FTC as PrEP is effective for cisgender men and women. In the Partners PrEP study, there was a 67% overall reduction in HIV acquisition in cisgender men and women and a 90% reduction in those with detectable drug in their blood [Baeten, et al. 2012]. In the TDF2 study, there was a 62% overall reduction in HIV acquisition, and there were only 2 seroconversions in participants who had detectable drug [Thigpen, et al. 2012]. However, the FEM-PrEP and VOICE trials did not demonstrate a benefit of TDF/FTC as PrEP for cisgender women, although subsequent analyses found that the lack of effect was associated with poor adherence to the prescribed daily PrEP regimen [Van Damme, et al. 2012]. TAF/FTC has not been studied in cisgender women. CAB LA was found to be statistically superior to TDF/FTC in the HPTN 084 study of cisgender women, in which there were 34 incident infections in the TDF/FTC arm but only 4 incident infections in the CAB LA arm, a difference driven by adherence to oral medication [Delany-Moretlwe, et al. 2022].

HIV-serodifferent couples: PrEP may be useful for individuals in a serodifferent partnership, even if the partner with HIV is taking suppressive ART. Data from the Partners in Prevention HSV/HIV Transmission Study and the HPTN 052 study demonstrated reductions up to 92% and 96%, respectively, in HIV transmission risk in serodifferent heterosexual couples when the partner with HIV was on suppressive ART [Cohen, et al. 2011]. HIV is transmissible if an individual’s viral load is not fully suppressed, which may take up to 6 months or longer after ART initiation. Once an undetectable viral load is achieved and maintained, HIV is not sexually transmissible [Mujugira, et al. 2016]. For more information, see the NYSDOH AI U=U Guidance for Implementation in Clinical Settings.

In the Partners Demonstration Project, use of TDF/FTC as PrEP as a “bridge” was highly effective in protecting the individual without HIV during the first 6 months of a partner’s ART. Subsequently, in the Partner, Partner 2, and Opposites Attract studies, there were no sexual transmissions between serodifferent partners when the partner with HIV had an undetectable viral load [Baeten, et al. 2016]. In September 2017, the NYSDOH endorsed the undetectable = untransmittable (U=U) consensus statement from the Prevention Access Campaign [Prevention Access Campaign 2019; NYSDOH 2017].

In a serodifferent partnership, the partner who does not have HIV may decide to use PrEP even if the partner with HIV has achieved an undetectable viral load with ART. Although this supplemental protection is likely not necessary in light of U=U data supporting treatment-as-prevention, PrEP should be discussed as an option for prevention and offered when appropriate. It is important to note that the partner without HIV may choose to take PrEP for other reasons, including if they have additional sex partners, are unsure of a sex partner’s viral load or ability to maintain viral suppression, or feel more secure about and in control of their sexual health with the protection of PrEP.

Although the efficacy of TDF/FTC as PrEP during attempts to conceive has not been formally studied, it is an option for individuals who do not have HIV, and evidence suggests that it does not affect male fertility [Were, et al. 2014] and is safe during the periconception period [Mugo, et al. 2014]. TAF/FTC has not been studied in the context of attempts to conceive.

People who inject drugs: The Bangkok Tenofovir Study is the only randomized controlled trial of PrEP in people who inject drugs [Choopanya, et al. 2013]. PrEP efficacy with TDF (alone) in this study was 49%, although restricting analysis to those with detectable drug in their blood increased efficacy to 74%.

PrEP for Adolescents

Modeling studies have shown the potential for PrEP to be highly effective at reducing HIV incidence among adolescent MSM, directly through use by adolescents and indirectly by reducing HIV prevalence among their sex partners [Hamilton, et al. 2019; Goodreau, et al. 2018].

TDF/FTC: In May 2018, the U.S. Food and Drug Administration (FDA) approved the use of TDF/FTC as PrEP in adolescents weighing ≥35 kg [FDA 2018]. The Centers for Disease Control and Prevention and the International Antiviral Society–USA previously extended the indication for TDF/FTC to include PrEP for adolescents at increased risk of acquiring HIV [CDC(b) 2018; Marrazzo, et al. 2014].

To date, there is no evidence of increased TDF/FTC toxicity in adolescents taking this combination as part of an ART regimen. TDF/FTC as PrEP was safe and effective in adolescents, with no renal events or bone fractures noted [Hosek, et al. 2017]. Concerns regarding bone loss in younger age groups have been raised, with 2 studies reporting a decline in bone mineral density [Havens, et al. 2017]. Bone density changes associated with TDF use are reversible on discontinuation in adults and MSM 18 to 22 years old [Hosek, et al. 2017]. Data on bone density recovery after discontinuation of TDF/FTC as PrEP are not available for adolescents <18 years old. Studies are in progress to determine the safety of TDF/FTC for adolescents over long periods of time.

TAF/FTC: In October 2019, the FDA approved use of this regimen as PrEP in adults and adolescents weighing ≥35 kg [FDA(a) 2019]. There are no specific data on bone safety in adolescents taking TAF/FTC as PrEP; however, given the more favorable bone biomarkers of TAF compared with TDF, TAF may have an advantage in MSM and transgender female adolescents who have not achieved bone maturation, but this advantage is theoretical. Without clinical data, a clear recommendation cannot be made at this time.

CAB LA: In December 2021, CAB LA was approved by the FDA for use in adolescents ≥12 years old weighing ≥35 kg [FDA(b) 2021].

Assessment and Counseling Before PrEP Initiation

Engagement in primary care: PrEP is an integral part of sexual health and well-being. Developing an HIV prevention plan that includes PrEP offers care providers the opportunity to engage individuals in primary care. Clinicians may use this opportunity to encourage age-appropriate health screenings, substance use screening and interventions, linkage to specialty services, and other health maintenance activities, such as immunizations (e.g., hepatitis A and B vaccines, human papillomavirus vaccine for patients ≤45 years old, and meningococcal vaccine when appropriate).

Patient education: Patient education is vital to shared decision-making and the success of PrEP as part of a comprehensive HIV prevention plan. Educate candidates about risks, benefits, and the choice of oral versus injectable PrEP. Discuss individual preferences, needs, and circumstances. Adherence may improve when patients participate in medication-related decisions [Johnson, et al. 2012] and are informed about the strong efficacy of PrEP when taken as directed (see guideline sections Choosing and Prescribing a PrEP Regimen > Engagement in Care and Adherence). Education provided in the individual’s native or preferred language and tailored to the individual’s level of comprehension will help ensure understanding of:

• How PrEP works
• The benefits and risks of PrEP
• The need for adherence to the dosing schedule for PrEP to be protective
• The importance of regular monitoring and adherence to the visit schedule
• How safer sex or safer drug injection practices decrease the risk of pregnancy and the risk of acquiring drug-resistant HIV, other sexually transmitted infections (STIs), and hepatitis C virus (see Be in the KNOW > Sex and HIV and NYSDOH Syringe Access and Disposal).

Health literacy assessment: Use a health literacy assessment to evaluate the individual’s knowledge of the:

• Purpose of PrEP
• Importance of adherence to PrEP
• Importance of scheduled HIV testing and routine monitoring
• Potential adverse effects of PrEP
• Process for obtaining regular pharmacy refills for PrEP
• Methods of paying for PrEP or access to payment assistance for PrEP medications and related care services

See An Introduction to Health Literacy from the National Library of Medicine for more details on the various aspects of health literacy, including tools for assessing health literacy.

Sex and drug use histories: A detailed HIV risk assessment includes obtaining a patient’s sexual history and drug use history and having a frank, open, and nonjudgmental discussion of risk-related behaviors. As indicated, this discussion may also include the offer of further counseling and referrals, such as for substance use treatment (see NYSDOH Office of Addiction Services and Supports: Treatment).

Status of sex partner(s) with HIV: The ART and viral load status of a sex partner with HIV may inform the discussion of risk. Sexual transmission of HIV does not occur when an individual with HIV has a persistently undetectable HIV viral load; nonetheless, an individual without HIV in a serodifferent partnership who does not have HIV may still elect to use PrEP [Prevention Access Campaign 2019; NYSDOH 2017; Rodger, et al. 2016]. If the patient’s partner has detectable virus and genotypic information is unavailable, knowledge of the partner’s ART regimen may be helpful. The risk of acquisition is increased when an individual is exposed to HIV that is resistant to the components of their PrEP regimen [Knox, et al. 2017; NYC Health 2016]. The potential for drug resistance is an important consideration when choosing a PrEP regimen. If there is a risk of drug resistance in a sex partner with HIV, it is essential to advise the individual without HIV to use additional prevention measures, including condoms.

Reproductive counseling: Inquire about the patient’s reproductive plans and provide preconception counseling when indicated. Determine whether the patient or the patient’s partner is pregnant or breastfeeding, intends to conceive, or is currently using hormonal or other contraception in addition to condoms [Bujan and Pasquier 2016; Lampe, et al. 2011; Vernazza, et al. 2011]. Counsel HIV-serodifferent couples who are considering the use of PrEP during attempts to conceive about the utility, safety, and possible risks of the medication (see guideline section Choosing and Prescribing a PrEP Regimen > PrEP During Pregnancy).

Psychosocial assessment: Assessments of psychosocial needs, strengths, challenges, mental health, and substance use are integral to good general medical practice. In the case of someone prescribed PrEP, such assessments enable clinicians to identify modifiable barriers to adherence and provide services and referrals to support adherence and retention in care.

PrEP in Comprehensive HIV Prevention Planning

A comprehensive HIV prevention plan includes counseling and education about PrEP options, adherence to PrEP, ongoing monitoring with laboratory tests, education about risk reduction, and discussion of additional HIV prevention options, including the use of condoms and safe drug injection practices [Blashill, et al. 2015; Daughtridge, et al. 2015; Liu, et al. 2014; Marcus, et al. 2014].

Risk reduction: At every visit, clinicians should encourage risk reduction through condom use, safer sex practices, and if applicable, safer injection techniques [Bramson, et al. 2015; Abdul-Quader, et al. 2013; Jarlais 2013]. Discussions about risk reduction should be tailored to patients’ specific needs. However, condom use is not a prerequisite for PrEP use.

Decreased condom use has been observed in some individuals taking PrEP and has been associated with a concomitant rise in other viral and bacterial STIs for which PrEP offers no protection; however, this is not a valid reason to withhold PrEP (see guideline section Ongoing Laboratory Testing > Routine Laboratory Testing > STI screening) [Traeger, et al. 2018; Werner, et al. 2018; Hojilla, et al. 2016; Kuhns, et al. 2016; Golub 2014; Liu, et al. 2013].

Risk compensation: Increased engagement in high-risk sexual behaviors, such as condomless sex or multiple sex partners, can lead to an increase in STI incidence and is sometimes cited by care providers as a reason not to offer PrEP. A meta-analysis of 20 studies found that rates of sexual risk behaviors and STIs in MSM taking PrEP remained stable or decreased in the majority of the studies [Werner, et al. 2018]. In a separate meta-analysis limited to open-label studies in which participants knew they were receiving active drug, a majority of the studies reported an increase in condomless sex but no significant increase in the proportion of MSM participating in condomless sex, indicating that participants were not using condoms consistently before they started PrEP [Traeger, et al. 2018].

High baseline STI rates in PrEP clinical trial participants demonstrate that risk behavior often precedes engagement in PrEP care. Initiating PrEP care for individuals at risk for HIV provides an opportunity for routine STI screening and treatment. One modeling study demonstrated that increased PrEP engagement along with routine STI screening and treatment would lower STI rates through detection and treatment of asymptomatic STIs that might otherwise remain undiagnosed. Modeling indicated that STI rates decline more rapidly as higher numbers of at-risk individuals initiate PrEP and related STI screening services, with an even greater reduction in STIs the more frequently STI testing occurs, even in the event of a 40% to 80% decrease in condom use [Jenness, et al. 2017].

PrEP after PEP: Patients who remain at increased risk of HIV exposure after completing a course of nPEP and who are negative for HIV at the 4-week test should be offered PrEP to begin immediately after the last dose of nPEP.

Contraindications to PrEP Use

HIV infection: The 2-drug PrEP regimens of TDF/FTC and TAF/FTC and the single-drug regimen of CAB LA are not adequate for treating established HIV infection; therefore, PrEP should not be initiated unless an individual is tested for HIV within 1 week before the proposed initiation. If HIV infection is confirmed, PrEP should immediately be converted to a fully suppressive HIV treatment regimen. For more information, see the NYSDOH AI guidelines Rapid ART Initiation and Selecting an Initial ART Regimen.

Renal dysfunction: TDF can cause renal toxicity and is contraindicated for patients with a CrCl <60 mL/min at the time of PrEP initiation [FDA 2016]. There are no data for adjusting TDF dosing in those with an estimated CrCl <50 mL/min.

TAF/FTC can be initiated in individuals with a creatinine clearance ≥30 mL/min and can be used in cisgender MSM and transgender women who have a CrCl <60 mL/min on initiation or a CrCl that drops to <50 mL/min while taking TDF/FTC.

Increased monitoring for adverse effects is appropriate for individuals with a CrCl <30 mL/min receiving CAB LA. Serum creatinine levels can vary and be affected by factors other than renal disease; therefore, before a decision is made to forgo oral PrEP, decreased CrCl should be verified through repeat testing, and other causes of spurious creatinine elevation (e.g., use of creatine-containing protein supplements) should be ruled out. Potentially reversible causes, such as the use of nonsteroidal anti-inflammatory medications, may also be addressed.

CAB LA is an appropriate PrEP option for individuals who cannot take a tenofovir-containing regimen because of renal dysfunction. To decrease drug exposure, on-demand dosing of TDF/FTC may also be considered when appropriate for cisgender MSM with borderline renal function or other kidney disease with a preserved calculated CrCl (see guideline section Choosing a Preferred PrEP Regimen > Preferred Oral Regimen for Daily or On-Demand Dosing: TDF/FTC).

When medication cannot be used for PrEP, education regarding other prevention options, such as condom use and safer sex practices, is essential.

PrEP Failure

HIV acquisition despite adherence to PrEP is rare. PrEP failure is directly related to suboptimal adherence in all but a small number of cases. In most cases of HIV acquisition despite adherence to PrEP, there was unrecognized HIV infection at the time of PrEP initiation.

There are case reports of individuals who acquired HIV despite adherence to TDF/FTC as PrEP, measured by tenofovir concentration in hair or dried blood spot samples. These case reports have noted that some individuals were exposed to HIV that was resistant to tenofovir and emtricitabine [Knox, et al. 2017; NYC Health 2016]. One individual acquired HIV with mutations that should still have conferred sensitivity to TDF/FTC [Cohen, et al. 2019]. Another acquired wild-type virus while using PrEP [Hoornenborg(a), et al. 2017]. It is theorized that in the case of wild-type virus acquisition despite good adherence, exposure to HIV was potentially very high given the number of condomless exposures over the 6-month period and the presence of rectal STIs.

PrEP failures with CAB LA were rare and mainly occurred before the initiation of study drug, during oral lead-in, in individuals who missed a scheduled injection, or during the tail phase after treatment was discontinued. In the HPTN 083 study, 6 individuals acquired HIV despite on-time CAB LA injections [Landovitz, et al. 2022; Landovitz, et al. 2021]. Analysis is under way to better understand these failures. In the HPTN 084 study, there were no incident HIV infections with on-time CAB LA injections in cisgender women [Marzinke(b), et al. 2021].

Although PrEP failure with CAB LA is rare, integrase resistance mutations were found in 5 of 9 participants with a resistance test result in the HPTN 083 study [Marzinke(a), et al. 2021]. There were 4 PrEP failures with CAB LA in the HPTN 084 study, with one infection occurring in an individual who received on-time injections. There was no finding of integrase resistance among these participants [Marzinke(b), et al. 2021]. There is concern with long-acting injectable medications about the slow decay in drug levels over time once the medication is stopped and that individuals who acquire HIV during the CAB LA tail phase will develop integrase resistance. It is reassuring that in the HPTN 083 study, none of the individuals who acquired HIV during the tail phase had integrase resistance mutations.

Comparison of Available Regimens

All current PrEP options are highly effective when taken as directed. Shared decision-making allows patient preferences and clinical considerations to guide the choice of the best PrEP option for each candidate (see Tables 1 and 2, below).

Time to Protection

The time to protection against HIV infection after PrEP initiation is not definitively established. No studies have directly assessed time to protection, and the site of PrEP action in blood, rectal, and genital tissues has not been settled. Most of what is known is from animal studies, human tissue studies, and pharmacokinetic modeling. There are no studies with clinical endpoints. In animal models and observational studies, post-exposure prophylaxis has been effective if initiated 36 to 72 hours after exposure, which raises questions about the specific drug concentrations in tissue required to protect against HIV infection.

TDF/FTC: Early pharmacokinetic modeling data demonstrated that 7 days of daily TDF/FTC for PrEP are required to achieve maximal protective concentrations in rectal tissue, and 20 days of daily dosing are required to achieve maximal protective concentrations in cervicovaginal tissue [Louissaint, et al. 2013; Anderson, et al. 2012; Patterson, et al. 2011]. No data are available on protective concentrations of TDF/FTC in penile tissue. Based on these data, the 2017 Centers for Disease Control and Prevention and NYSDOH AI PrEP guidelines recommended 7 days of TDF/FTC as PrEP for rectal exposure and 20 days of PrEP for vaginal, penile, and injection exposures to achieve protection.

Other pharmacokinetic modeling data suggest that TDF/FTC is likely protective within 1 week of dosing in rectal and genital compartments and peripheral blood mononuclear cells (PBMCs) [Hendrix, et al. 2016; Seifert, et al. 2016]. Emtricitabine triphosphate (active metabolite of emtricitabine) reaches steady-state and therapeutic concentrations very quickly in vaginal tissue, and tenofovir diphosphate (active metabolite of tenofovir) reaches concentrations more slowly, potentially affording vaginal protection quite early from emtricitabine triphosphate while tenofovir diphosphate concentrations accumulate [Cottrell, et al. 2016; Seifert, et al. 2016].

Some guidelines have suggested shorter intervals to PrEP protection with TDF/FTC. Both the 2017 World Health Organization (WHO) and the 2018 British HIV Association (BHIVA) guidelines recommend a 7-day PrEP lead-in for protection against HIV via vaginal and injection exposures [BHIVA 2019; WHO 2017]. The WHO guidelines recommend a time to protection of 7 days for all sites of exposure, but the BHIVA guidelines advise that protection against rectal exposure is achieved 24 hours after an initial double (loading) dose, based on the efficacy shown in the IPERGAY study of on-demand TDF/FTC and pharmacokinetics indicating achievement of protective concentrations of TDF/FTC sooner with a loading dose. Although concrete guidance on efficacy would be best, and accumulating evidence points to an earlier time to protection for vaginal exposure, a definitive answer to this question is not yet available, and experts disagree in their interpretation of the evidence [AVAC 2017].

TAF/FTC: Time to protection for TAF/FTC is also unclear. TAF had a faster time to 90% effective concentrations (EC₉₀) than TDF (4 hours vs. 3 days) and significantly higher steady-state concentrations in PBMCs than TDF/FTC as PrEP [Ogbuagu, et al. 2021], which may confer a clinical benefit in terms of time to protection and adherence forgiveness, but this is preliminary evidence and further evaluation is needed.

CAB LA: At this time, there are no data available on time to protection for CAB LA, and specific guidance cannot be provided.

Preferred Oral Regimen for Daily or On-Demand Dosing: TDF/FTC

When TDF/FTC is preferred: TDF/FTC is the preferred oral regimen for PrEP because of its proven efficacy and safety in clinical trials, its suitability for use as PrEP in most populations (including individuals who inject drugs), and its cost, which is lower than that of TAF/FTC. However, for cisgender MSM and transgender women with preexisting renal disease or osteoporosis, TAF/FTC is the preferred oral regimen; see below.

Daily dosing: The FDA-approved dosing of TDF/FTC as PrEP is 1 tablet daily by mouth with or without food [FDA 2016].

For cisgender MSM, the data on daily dosing of TDF/FTC are more robust than for on-demand dosing, with longer follow-up. Daily dosing remains the preferred dosing strategy.

On-demand dosing: For TDF/FTC as PrEP, an on-demand dosing strategy (also called intermittent, event-driven, or coitally timed PrEP) is an option for MSM when lifestyle, sexual practices, or stated preferences make it a more acceptable choice.

On-demand dosing of TDF/FTC is not recommended for protection against vaginal sexual exposure, blood exposure through injection drug use, or in individuals with HBV infection. It should be used with caution in transgender women taking gender-affirming hormones.

When used on-demand, TDF/FTC is taken as a “2-1-1” regimen:

• 2 to 24 hours before sex: Take 2 TDF/FTC tablets (closer to 24 hours is preferred), followed by
• 24 hours after sex: Take 1 TDF/FTC tablet, then
• 48 hours after sex: Take 1 TDF/FTC tablet
• If sex occurs again: Take 1 TDF/FTC tablet daily until 48 hours after the last sex act, effectively becoming daily PrEP for as long as sex continues.

Considerations for on-demand PrEP: Successful on-demand PrEP requires planning ahead for sex by at least 2 hours. Patients have to review their usual practices in planning for sex to assess the feasibility of this approach, and clinicians have to ensure that patients understand the complex dosing schedule.

The logistical challenge of determining the amount of medication to prescribe for patients taking PrEP on demand should not preclude using this strategy when it is appropriate. Switching back and forth between daily and on-demand PrEP may be an appealing, evidence-based option for some individuals [Molina, et al. 2022; Hoornenborg(b), et al. 2017].

Evidence for the efficacy of on-demand dosing includes the results of the IPERGAY and Prevenir studies, which found that “2-1-1” dosing effectively prevented HIV acquisition in MSM [Molina, et al. 2015]. Concerns have been raised as to whether the efficacy observed in the IPERGAY study resulted from the frequency of dosing when PrEP was used on-demand in this study. The average number of PrEP doses taken per month by participants in the IPERGAY study was 15 (approximately 4 doses per week) [Molina, et al. 2015], which was the minimum level of adherence necessary for protection in the iPrEx study [Anderson, et al. 2012]. The iPrEx-OLE study, an open-label extension of the iPrEx study, confirmed that 4 or more doses of TDF/FTC as PrEP per week were protective [Grant, et al. 2014]. However, in a substudy of IPERGAY, PrEP dosed on demand remained effective even in participants with less frequent sexual activity [Antoni, et al. 2020]. The HPTN 067 ADAPT study investigated daily versus time-driven (twice per week with an additional dose after sex) versus event-driven dosing and found that adherence with event-driven dosing was lower than daily dosing [Velloza, et al. 2019].

TDF/FTC as PrEP for transgender women: Studies have shown that estrogen use may lower tenofovir levels in the plasma of transgender women compared with cisgender men, but more recent studies call these findings into question. Levels of adherence needed for transgender women using estrogen and taking TDF/FTC for PrEP may be higher than for cisgender men, but the drug concentrations achieved with daily dosing of TDF/FTC as PrEP will confer protection (see guideline section PrEP for Individuals at Risk of Acquiring HIV > PrEP Candidates > Transgender women).

The significance of this potential difference in tenofovir concentrations with regard to on-demand dosing for transgender women is less clear; therefore, on-demand dosing cannot be uniformly recommended for this population. However, if neither daily oral dosing nor injections are viable options for a transgender woman at high risk of acquiring HIV, it is reasonable to discuss the risks and benefits of on-demand dosing, including the lack of data, and engage the patient in informed, shared decision-making regarding this dosing strategy.

Not recommended: The effectiveness of on-demand TDF/FTC as PrEP for vaginal exposure has not been established. In the HPTN 067 ADAPT study, levels of orally administered tenofovir were much lower in the vagina than in the anal compartment [Anderson, et al. 2016]. Other data suggest that vaginal sex requires nearly 100% adherence to PrEP to achieve protective levels [Cottrell, et al. 2016]. Without more data, the differential pharmacokinetics for vaginal exposure with TDF/FTC as PrEP precludes a recommendation for on-demand dosing for cisgender women or transgender men engaging in receptive vaginal sex. Data are also lacking for men who have sex with women.

On-demand dosing cannot be recommended for protection against blood exposure. Based on data from the Bangkok Tenofovir Study, which studied TDF alone in people who inject drugs, it appears that the rate of PrEP adherence required for protection must be higher for people who inject drugs than for other populations [Choopanya, et al. 2013].

Common adverse effects: In clinical trials of TDF/FTC as PrEP, the most common adverse effects were nausea, headache, abdominal pain, and dizziness, which were mild and short-lived [McCormack, et al. 2016; Thigpen, et al. 2012; Grant, et al. 2010]. Most adverse effects peaked at 1 month and generally resolved within 3 months [Glidden, et al. 2016]. In a study comparing TAF/FTC and TDF/FTC as PrEP, both regimens were well tolerated, with diarrhea the only adverse effect in >10% of individuals in either arm [Mayer, et al. 2020].

Renal impairment and loss of bone density: Both have been observed in individuals taking TDF/FTC as treatment for HIV, predominantly in studies of TDF/FTC combined with a third drug containing the pharmacokinetic booster ritonavir or cobicistat. Studies comparing unboosted TDF/FTC and TAF/FTC for HIV treatment found no difference in adverse events between the 2 arms [Hill, et al. 2018]. A meta-analysis of 13 trials of TDF/FTC used as PrEP found no difference in serious adverse events between TDF/FTC and placebo [Pilkington, et al. 2018]. The meta-analysis did find a borderline statistically significant difference in creatinine elevation of all grades when comparing TDF/FTC with placebo and adding in grade 1 and 2 elevations.

The DISCOVER study, which compared TDF/FTC with TAF/FTC for PrEP, did find a small but statistically significant difference between biomarkers of renal and bone dysfunction favoring TAF/FTC, although no difference was found in clinical adverse outcomes [Mayer, et al. 2020]. Although renal dysfunction is uncommon in individuals taking TDF/FTC as PrEP, and especially those who are younger [Gandhi, et al. 2016], regular laboratory monitoring is necessary during use of TDF/FTC or TAF/FTC (see Table 4: Recommended Routine Laboratory Testing for Patients Taking PrEP). If an increase in serum creatinine or a decrease in calculated CrCl is observed, evaluate potential causes other than TDF or TAF use. Discontinuation or interruption of TDF/FTC as PrEP is appropriate if other causes are ruled out or if CrCl drops to <50 mL/min (confirmed on 2 readings) for any reason. TAF/FTC is indicated for cisgender MSM and transgender women with CrCl ≥30 mL/min. When appropriate, on-demand dosing of TDF/FTC can also be considered to decrease drug exposure for MSM with borderline renal function.

Bone density losses with TDF/FTC as PrEP are minimal and have not been associated with bone fractures [Havens, et al. 2020; Spinelli, et al. 2019]. No additional monitoring of bone mineral density is recommended.

For cisgender MSM and transgender women at high risk of fracture due to osteoporosis or at increased risk of developing osteoporosis, TAF/FTC is the preferred oral regimen and should be considered.

Alternative Oral Regimen for Daily Dosing: TAF/FTC

TAF/FTC is an alternative PrEP regimen for cisgender MSM and transgender women.

When TAF/FTC is preferred: It is the preferred oral regimen for cisgender MSM and transgender women with preexisting renal disease or osteoporosis, and it may be preferable in MSM and transgender women with multiple risk factors for renal disease or osteoporosis.

Daily dosing: The FDA-approved dosing of TAF/FTC as PrEP is 1 tablet daily by mouth with or without food [FDA(a) 2019].

On-demand dosing: On-demand dosing has not been studied for TAF/FTC; this regimen should not be dosed on-demand in any population.

TAF/FTC was noninferior to TDF/FTC in cisgender MSM and in the small group of transgender women who participated in the DISCOVER trial, a large, double-blinded, active-control study [Mayer, et al. 2020]. In that trial, the TAF component was associated with improved biomarkers for renal and bone safety; however, the clinical significance of these changes is unclear, and there was no difference in clinical outcomes regarding adverse events. TAF use was associated with small increases in weight gain and low-density lipoprotein (LDL) cholesterol levels compared with TDF, but the clinical significance of these differences is unclear [Mayer, et al. 2020; Orkin, et al. 2018].

TAF may have an advantage in MSM and transgender female adolescents who have not achieved bone maturation, given favorable bone biomarkers compared with TDF, but this advantage is theoretical, and without clinical data, a clear recommendation cannot be made at this time [Havens, et al. 2020; Mayer, et al. 2020; Spinelli, et al. 2019; Hosek, et al. 2017].

TAF/FTC has not yet been studied for vaginal exposures in human trials. Study results to date suggest that tenofovir concentrations in vaginal tissue after administration of TAF are lower than for TDF [Cottrell, et al. 2017], although TAF does reach high intracellular concentrations in PBMCs, and oral TAF/FTC was effective in preventing vaginal simian HIV infections in macaques [Massud, et al. 2019]. Further study of TAF/FTC for protection in vaginal and injection HIV exposures is needed. TAF/FTC has also not been studied in insertive partners in the context of vaginal sex.

Common adverse effects: In a study comparing TAF/FTC and TDF/FTC as PrEP, both regimens were well tolerated, with diarrhea the only adverse effect in >10% of individuals in either arm [Mayer, et al. 2020].

Manage adverse effects: Two weeks after oral PrEP initiation, a care team member should follow up either in person or by telephone to assess and address adverse effects and offer advice for management until they abate. Gastrointestinal adverse effects can be alleviated by taking PrEP medications with food or antidiarrheal agents, anti-gas medications, and antiemetics. In the iPrEx [Grant, et al. 2014; Grant, et al. 2010] and Partners [Mujugira, et al. 2016] trials of TDF/FTC as PrEP, rash was not reported as a common adverse effect. Patients who develop a rash while taking TDF/FTC or TAF/FTC as PrEP should be assessed for syphilis and acute HIV [Apoola, et al. 2002].

Preferred Injectable Regimen: CAB LA Every 2 Months

In December 2021, the FDA approved CAB LA for use as PrEP for sexual exposures in adults and adolescents weighing ≥35 kg [FDA(b) 2021].

HPTN 083, a study of a diverse multinational population of 4,566 MSM and transgender women, found CAB LA to be statistically superior to TDF/FTC in MSM and transgender women [Landovitz, et al. 2021]. HPTN 084, a study of 3,224 cisgender women in 7 sub-Saharan African countries, also found CAB LA to be statistically superior to TDF/FTC [Delany-Moretlwe, et al. 2022]. Both studies found CAB LA to be safe and well tolerated, with the main adverse effects being injection site reactions, which were generally mild and decreased in incidence over time.

When CAB LA is preferred: CAB LA is a preferred agent for protection against sexual exposure to HIV in adults and adolescents weighing ≥35 kg.

CAB LA is a preferred agent for individuals who are open to injectable PrEP, because of its statistically superior efficacy in preventing HIV compared with TDF/FTC and its protection against HIV through all types of sexual exposure [Delany-Moretlwe, et al. 2022; Landovitz, et al. 2021]. CAB LA is a good option when oral medication poses a challenge to PrEP use.

Oral CAB lead-in: In clinical trials of CAB LA, a 5-week oral CAB lead-in was administered to rule out adverse effects before patients received a long-acting injection [Delany-Moretlwe, et al. 2022; Landovitz, et al. 2021]. There are no data on the safety or efficacy of CAB LA when used for PrEP without an oral lead-in.

However, in clinical trials of injectable long-acting CAB plus rilpivirine (CAB/RPV LA) for HIV-1 treatment, omission of the oral lead-in was safe and did not interfere with achievement of adequate plasma CAB levels when injections were initiated [Orkin, et al. 2021]. There were no CAB safety concerns identified during the oral lead-in phase in trials of CAB/RPV LA as HIV treatment [Rizzardini, et al. 2020] or in trials of CAB as PrEP. As a result, the oral lead-in phase for CAB LA as PrEP is now optional.

Some care providers or patients concerned about ensuring tolerability before initiating a long-acting treatment may prefer an oral CAB lead-in. An important consideration in such cases is the potential risk of HIV acquisition for individuals who may struggle with adherence to daily oral medication. Of note, 3 of the 12 incident HIV infections in individuals using CAB as PrEP in the HPTN 083 study were acquired during the oral lead-in phase [Marzinke(a), et al. 2021]. Ongoing daily oral CAB is not FDA-approved or recommended as PrEP.

TDF/FTC (or TAF/FTC if appropriate) can be used as an alternative oral lead-in therapy for same-day initiation when oral CAB or CAB LA is not immediately available because of insurance or logistics issues. Some care providers may choose to briefly overlap oral TDF/FTC or TAF/FTC with CAB to maintain protection against HIV while CAB levels are attaining steady-state.

Oral CAB as bridge therapy: Oral CAB can also be used as bridge therapy when it is anticipated that an injection will be missed. Oral CAB is currently only available from a central pharmacy in collaboration with ViiV Healthcare. TDF/FTC (or TAF/FTC if appropriate) can also be used as bridge therapy when logistics impede timely access to oral CAB.

CAB LA injections: CAB LA as PrEP is administered as a 600 mg IM injection every 2 months after the first 2 injections are given 4 weeks apart. See Box 2, below, for details on the preparation and administration of CAB LA as PrEP.

The median time from the last injection to when CAB LA concentrations decreased below the lower limit of quantification was 43.7 weeks for male participants and 67.3 weeks for female participants in the HPTN 077 trial [Landovitz, et al. 2020]. Because of the long decay time for CAB LA to be eliminated, if a patient chooses to discontinue CAB LA and there is an ongoing risk for HIV exposure, they should be transitioned to an oral PrEP regimen 2 months after the last injection. If risk is ongoing, oral PrEP should be continued for at least 1 year to prevent the acquisition of INSTI-resistant HIV. However, it is reassuring that none of the patients in the HPTN 083 study who acquired HIV during the tail phase had INSTI resistance mutations [Landovitz, et al. 2021].

Adverse effects: In the clinical trials noted above, CAB LA as PrEP was well tolerated. Adverse reactions observed in at least 1% of participants included injection site reactions, diarrhea, headache, pyrexia, fatigue, sleep disorders, nausea, dizziness, flatulence, abdominal pain, vomiting, myalgias, rash, decreased appetite, somnolence, back pain, and upper respiratory tract infection; however, almost all were grade 1 level effects. The most common adverse effects were injection site reactions in 81% of HPTN 083 study participants and 32% of HPTN 084 study participants. Reactions were mostly mild or moderate in intensity and decreased in frequency and intensity over time. Median onset was 1 day after injection in the HPTN 083 trial and lasted a median of 3 days. Discontinuations due to injection site reactions were rare and occurred at a rate of 2.4% in the HPTN 083 trial and 0.0% in the HPTN 084 trial. Other studies have reported a strong preference for long-acting injectable medications despite injection site reactions [Tolley, et al. 2020; Murray, et al. 2018].

Metabolic effects: Mild weight gain was observed in MSM and transgender women receiving CAB LA as PrEP compared with TDF/FTC, but there was no significant difference in weight between the 2 study arms in cisgender women, and there was no significant effect on lipid levels [Delany-Moretlwe, et al. 2022; Landovitz, et al. 2021].

CAB LA implementation: The logistics of implementing an injectable option in PrEP programs may be challenging and requires institutional, clinician, and patient preparation. Medication storage, scheduling and reminders, tracking systems, and staffing levels must be addressed with implementation plans appropriate to each setting (see Box 3, below).

Engagement in Care

Engagement in care is a challenge for PrEP programs. Flexibility in visit frequency and provision of alternative modalities, such as telehealth, can enhance care access and engagement. The availability of both oral and injectable PrEP options increases choices for individuals and may also enhance persistence in care.

Challenges: Multiple studies have shown that persistence on PrEP remains a challenge [Wagner, et al. 2023; Blumenthal, et al. 2021; Chan, et al. 2016]. One study that examined PrEP programs in 3 midsized cities found the rate of persistence in PrEP care at 6 months to be 60%, owing to individual and structural barriers [Chan, et al. 2016]. “Overmedicalization” of PrEP care may pose a barrier to persistence by requiring healthy individuals to engage frequently with health care through at least quarterly clinic visits and laboratory tests. Although quarterly assessments remain the standard for oral PrEP monitoring, flexibility regarding in-person visits is encouraged when needed or appropriate. Quarterly laboratory testing is recommended even with a decision to adjust visit frequency, but flexibility for individual patients regarding this time frame is appropriate because quarterly screening is a best practice rather than an evidence-based recommendation. Barriers to engagement in care should be explored with all patients, and individualized solutions should be explored with those struggling to remain in care who wish to continue PrEP use. Novel models, such as annual visits with quarterly at-home HIV testing [Siegler, et al. 2019], are promising, and telemedicine visits should be encouraged when appropriate to remove structural barriers for patients having difficulty with PrEP persistence.

Injectable PrEP may increase PrEP uptake and persistence among individuals for whom regular oral medication is a barrier to care, those with preexisting renal disease, or those who prefer the convenience of an injection once every 2 months to daily oral PrEP. However, CAB LA as PrEP requires visits every 2 months for both monitoring and injections. This could be a barrier for patients who prefer visits only every 6 to 12 months (with quarterly laboratory tests in the interim), as indicated for current oral PrEP options, or who have life or work challenges that make visits every 2 months logistically challenging. Institutions will need sufficient appointment availability and flexibility in days and hours of care to increase access to care and persistence with CAB LA. Tracking systems and reminder calls can help increase adherence to injection visits. Alternative care models, including home visits for injections, will help increase access to this treatment.

Episodic PrEP: PrEP use may be noncontinuous, as individuals may cycle off and on PrEP based on fluctuations in their risk of acquiring HIV [Reed, et al. 2021]. Therefore, discontinuation of PrEP may not indicate program failure. However, for individuals who want to remain on PrEP, it is essential to remove barriers and individualize care.

Gender-affirming care: Transgender women have high rates of PrEP discontinuation [Scott, et al. 2019]. Providing gender-affirming and transition-related care to transgender individuals may increase PrEP uptake and persistence [Sevelius, et al. 2016]. Transgender women may avoid PrEP or miss doses because they are concerned that drugs active against HIV lower estrogen levels. Multiple studies have shown that TDF/FTC does not lower estrogen plasma concentrations [Blumenthal, et al. 2022; Grant, et al. 2021; Hiransuthikul, et al. 2019]. Addressing this directly with transgender women and providing reassurance regarding estrogen levels may improve their willingness to take and adhere to PrEP. Currently, there are no data directly evaluating the effect of TAF/FTC or CAB LA on estrogen plasma concentration; however, no interaction is expected based on the pharmacokinetic profiles of TAF/FTC and CAB LA and their lack of significant interactions with oral contraceptives.

Other services: Clinicians should partner with care providers within or outside of their organization to provide other services, including mental health and substance use treatment, case management, navigation and linkage services, housing assistance, and income/benefits assessments. Refer patients to support groups if indicated. However, PrEP should not be withheld from individuals who are not interested in primary care or who may choose to obtain PrEP from a location other than where they receive primary care.

Adherence

Challenges: Daily adherence to oral PrEP is challenging for some patients for a wide variety of complex and intersecting reasons, including pill counts and sizes, adverse effects related to PrEP medications, privacy concerns, PrEP-related stigma, neurocognitive disorders, mental health conditions, active substance use, psychological trauma, personal belief systems, travel requirements, occupation, and health literacy. Although the availability of a once-daily single-tablet oral option for PrEP is helpful to adherence, studies and real-world experience demonstrate ongoing challenges with adherence to daily oral PrEP for some individuals. The use of long-acting agents for PrEP can potentially address the adherence challenges that some individuals face, and studies have shown a high interest in long-acting agents for PrEP in the general population and in specific subpopulations [Philbin, et al. 2021; Koren, et al. 2020; Rael, et al. 2020; Meyers, et al. 2014]. CAB LA is the only long-acting injectable PrEP option currently approved by the FDA; however, other injectable and long-acting agents are under study.

The degree of adherence to TDF/FTC as PrEP required to prevent HIV varies by exposure site. Based on modeling studies of rectal exposure, 4 doses per week of TDF/FTC appears sufficient to protect against HIV [Grant, et al. 2014]; however, modeling studies also suggest that vaginal and injection HIV exposures require closer to 7 doses of TDF/FTC per week for efficacy [Cottrell, et al. 2016; Choopanya, et al. 2013; Patterson, et al. 2011]. There are no data on adherence needed for penile insertive exposure. Currently, no data are available regarding adherence levels required for TAF/FTC or CAB LA effectiveness.

Strategies for adherence support: In studies of TDF/FTC as PrEP, efficacy was highly dependent on adherence [Sidebottom, et al. 2018], and on-time injections of CAB LA are essential to avoiding viral breakthrough [Landovitz, et al. 2021]. Some reasons for decreased adherence are adverse effects, fear of long-term toxicity, perceived low risk of infection, insurance issues, depression, substance use, and difficulty with daily dosing. For patients who struggle with adherence to PrEP, strategies such as more frequent visits or contact with medical and nonmedical care providers may be helpful. Adherence decreased when visits went from monthly to quarterly in adolescent patients [Hosek, et al. 2017]. Assessing and addressing individual reasons for suboptimal adherence to PrEP is important [Goodreau, et al. 2018; Jenness, et al. 2016].

Some care providers use peer supporters to reinforce adherence to medication and appointments. If patients are consistently unable to adhere to an oral PrEP regimen despite interventions to improve adherence or if they decline to take oral PrEP daily, it may be appropriate to explore alternative dosing schedules, such as on-demand PrEP (for cisgender MSM only, with TDF/FTC), injectable PrEP, or seasonal or vacation use of PrEP. It may also be appropriate to discuss discontinuing PrEP and using other risk-reduction strategies that better meet the needs of the individual.

PrEP During Pregnancy

HIV acquisition risk is higher in pregnancy and is highest in the late pregnancy and early postpartum periods [Thomson, et al. 2018], and PrEP should be recommended if the risk of HIV exposure continues. Risk of perinatal transmission is also significantly higher during pregnancy and breastfeeding in cases of acute seroconversion [Drake, et al. 2014; Singh, et al. 2012]. Encourage pregnant individuals to inform their obstetric and pediatric care providers when using PrEP medications or any other prescription or over-the-counter medications.

TDF/FTC: Pregnancy is not a contraindication to the use of TDF/FTC as PrEP. Clinicians should counsel pregnant patients about the risks and benefits of continuing TDF/FTC for HIV prevention during pregnancy. Available data suggest that TDF/FTC as PrEP does not increase the risk of congenital anomalies (the use of ART medications during pregnancy is monitored through the Antiretroviral Pregnancy Registry). Conflicting results have been observed in studies of bone mineral density in infants born to women taking TDF as a component of ART for HIV [Siberry, et al. 2015; Vigano, et al. 2011]. One study suggested up to a 15% decrease in bone mineral density in infants exposed to TDF in utero compared with infants who were not exposed to TDF [Siberry, et al. 2015], whereas another study found no association between in utero TDF exposure and infant bone mineral density [Vigano, et al. 2011]. In a study of pregnant women who did not have HIV in whom TDF was used as prophylaxis to prevent transmission of HBV, there was no difference in bone mineral density at 1 year in TDF-exposed infants compared with infants not exposed to TDF in utero [Salvadori, et al. 2019].

Infant exposure to TDF/FTC through breast milk is much lower than TDF exposure in utero; evidence to date suggests that TDF is safe during breastfeeding [Liotta, et al. 2016; Ehrhardt, et al. 2015]. Longer-term follow-up studies of TDF-exposed infants are ongoing and will provide further information and guidance on the use of PrEP in this population [Mugwanya, et al. 2016]. Although data on breastfeeding effects are limited, TDF/FTC is commonly prescribed as part of an ART regimen before, during, and after pregnancy, and the benefit of preventing HIV infection and subsequent perinatal transmission among individuals at increased risk outweighs the theoretical concerns associated with prescribing TDF/FTC as PrEP during breastfeeding, pending further data.

CAB LA: There are insufficient data on the safety of CAB LA as PrEP in pregnancy, and CAB LA should be used during pregnancy only if the expected benefit justifies the potential risk to the fetus. In animal reproduction studies, parturition was delayed, and stillbirths and neonatal deaths increased when oral CAB was given at >28 times the recommended human dose [FDA(a) 2021]. More data should become available over time. In the interim, care providers should recommend that individuals planning to conceive or become pregnant while receiving CAB LA as PrEP switch to TDF/FTC if it is an appropriate option and they wish to continue PrEP.

HIV Testing

Risk assessment: Before starting PrEP, all patients should be evaluated for possible HIV infection and assessed for acute HIV. The goal of risk assessment is to identify potential HIV exposures in the prior 4 weeks and flu- or mono-like symptoms in the previous 6 weeks.

Both an HIV-1/2 Ag/Ab combination immunoassay and an HIV RNA test should be performed within 1 week before PrEP is started. HIV RNA (viral load) testing is performed at baseline to rule out acute HIV infection regardless of reported risk, as individuals may be reluctant to disclose a recent potential risk exposure. If a confirmed negative result is not available at the time of the patient’s initial visit, a rapid HIV-1/2 test should be performed for same-day PrEP initiation.

Drug-resistant virus has been found in patients with undiagnosed HIV who initiated PrEP with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC; brand name Truvada), tenofovir alafenamide/emtricitabine (TAF/FTC; brand name Descovy), or CAB LA [Landovitz, et al. 2021; Cox, et al. 2020; Molina, et al. 2022; Lehman, et al. 2015].

Same-day initiation of oral PrEP: Once laboratory specimens are obtained (see Table 3, below), PrEP may be initiated while test results are pending if the patient has not had symptoms or signs of acute HIV in the prior 6 weeks, has no history of renal disease, and no risk exposures in the past 72 hours requiring PEP, as long as laboratory results will be available and addressed within 7 days and a rapid HIV test result is negative. In HIV care, the rapid start of treatment has been shown to better engage patients in care [Ford, et al. 2018]. Same-day initiation of PrEP has been shown to be safe, and delayed initiation of PrEP has been associated with a significant rate of loss to follow-up [Kamis, et al. 2019; Mikati, et al. 2019]. Same-day PrEP initiation may engage patients more fully in care and reduce exposures to HIV while test results are pending and encourages immediate attention to insurance coverage for PrEP or identification of other options for payment if needed.

Same-day PrEP initiation risks starting a nonsuppressive ART regimen in someone with HIV. However, if laboratory results are available promptly, then the PrEP regimen for an individual who tests positive for HIV can be intensified to a fully suppressive ART regimen, and a referral for HIV care can be made. If the baseline HIV testing result is positive after CAB is initiated, the care provider should consult with an experienced HIV care provider regarding the best way to intensify the PrEP regimen to a fully suppressive ART regimen (see guideline section Managing a Positive HIV Test Result). TAF/FTC may require a prior authorization, which makes same-day initiation a challenge, but generic TDF/FTC is usually available for same-day initiation.

Same-day initiation of an oral CAB lead-in or CAB LA: If prior insurance authorization is required, same-day CAB initiation (oral or injection) may not be an option. Implementation challenges such as stocking and storing medications in advance may also be prohibitive. If same-day CAB initiation is not an option, prescription of an oral regimen should be discussed as an interim option while barriers to accessing CAB LA injections are addressed.

Although delays such as insurance barriers may impede initiation of PrEP, the overall goal should be same-day initiation in patients without renal disease, need for PEP, or signs or symptoms of acute HIV.

Initiating PrEP during the HIV testing window period: The “window period” is the time between when an individual has acquired HIV and when a diagnostic test can detect infection. The median time to positivity is 12 days for an HIV viral load test and 18 days for a laboratory-based HIV-1/2 Ag/Ab combination immunoassay; however, the 99th percentile for a positive test is 33 days for an HIV viral load test and 42 days for a laboratory-based HIV-1/2 Ag/Ab combination immunoassay [Delaney, et al. 2017]. Clinicians should not defer initiation of PrEP in candidates who, based on their reported sexual and drug use exposures, may be in the window period for seroconversion; doing so risks additional exposures and significant delays in PrEP initiation. Repeat HIV testing 1 month after initiation to help identify potentially positive individuals in a timely manner (see guideline section Ongoing Laboratory Testing).

Recommended Laboratory Testing

Table 3, below, lists the baseline laboratory tests that should be performed at the pre-prescription visit for individuals who will initiate PrEP. When an individual is engaged in care to receive PrEP, primary healthcare may be offered as indicated, including vaccinations against hepatitis A and B viruses, human papillomavirus, meningococcus, influenza, and COVID-19.

For more information, see Centers for Disease Control and Prevention Recommended Adult Immunization Schedule for Ages 19 Years or Older, United States, 2022 and COVID-19 ACIP Vaccine Recommendations and NYSDOH Health Advisory: NYSDOH Meningococcal Vaccine Recommendations for HIV-Infected Individuals and Those at High Risk of HIV Infection.

HIV Testing

For individuals taking PrEP, routine HIV testing is recommended for early detection of PrEP failure. None of the available regimens are adequate for treating acute or chronic HIV infection. Continued use of only TDF/FTC, TAF/FTC, or CAB LA in the presence of HIV may lead to viral resistance to these drugs.

Routine HIV testing with oral PrEP: A quarterly (every 3 months) HIV-1/2 Ag/Ab combination immunoassay is recommended for individuals taking TDF/FTC or TAF/FTC as PrEP. Quarterly HIV RNA testing is not needed for patients who are stable on oral PrEP.

Breakthrough HIV infections among individuals adherent to oral PrEP are rare. When failure of an oral PrEP regimen (TDF/FTC or TAF/FTC) occurs, it is usually associated with poor adherence and is infrequently associated with the development of resistance. When drug resistance does develop, it is typically an M184V/I resistance mutation, which has little or no effect on subsequent response to HIV treatment. The development of the K65R resistance mutation (associated with tenofovir) has rarely been reported [van de Vijver, et al. 2021; Gibas, et al. 2019]. Unrecognized acute HIV infection at the time of PrEP initiation carries the highest risk for developing resistance mutations [van de Vijver, et al. 2021; Gibas, et al. 2019]. For this reason, this committee recommends that clinicians perform baseline HIV RNA testing for all patients before initiating PrEP.

In the HPTN 083 study, there was less delay in detection of new HIV infections with seroconversion for participants receiving TDF/FTC than for those receiving CAB LA. There were a median of 34 days and 31 days of unrecognized baseline and incident HIV infections, respectively, in the TDF/FTC arm, compared with 62 days and 98 days, respectively, in the CAB LA arm [Marzinke(a), et al. 2021].

HIV RNA testing is recommended for individuals who report an interruption in PrEP of more than 1 week or report missing doses of PrEP during a time of sexual activity since the preceding visit.

Testing for HIV every 3 months is based on good practice rather than evidence. If HIV testing is missed, every effort should be made to avoid interruption of PrEP, as the potential harm of discontinuing PrEP outweighs the theoretical risk of delaying HIV testing in a stable patient. It is reasonable to provide an additional month of PrEP and plan for HIV testing as soon as possible.

In-office visits are not a requirement for ongoing prescription of PrEP. It is reasonable for patients established on oral PrEP to be tested for HIV every 3 months, either on-site or at an outside laboratory, and to see their care providers every 6 to 12 months. Requiring in-office visits may create a barrier to PrEP access for some individuals. Alternative monitoring models, such as at-home testing and telehealth visits, can decrease PrEP access and monitoring barriers.

Routine HIV testing with CAB LA: CAB LA injections are administered at in-office visits every 2 months; there are currently no alternative administration models. HIV testing should be performed at the end of the oral CAB lead-in (if implemented) and at every injection visit. Breakthrough HIV infections were observed in 4 individuals who received on-time CAB LA injections in the HPTN 083 study, and were also observed during the oral CAB lead-in phase and during treatment interruptions [Marzinke(a), et al. 2021]. Adherence to the CAB LA injection schedule is not a guarantee of protection against HIV acquisition.

HIV testing should include an HIV-1/2 Ag/Ab combination immunoassay and HIV RNA test using FDA-approved tests and sample types (plasma or serum). Studies have reported atypical test results with missed diagnoses when the standard Centers for Disease Control and Prevention/American Public Health Laboratories Laboratory Testing Algorithm in Serum/Plasma was used with individuals on antiretroviral therapy (ART) at the time of HIV seroconversion. In the HPTN 083 study, there was a median delay of 62 days from the time of infection to HIV diagnosis for unrecognized baseline infections in individuals on CAB LA, and of 98 days for incident infections, with the subsequent development of integrase resistance mutations in 5 individuals [Eshleman, et al. 2022; Marzinke(a), et al. 2021].

Because there may be delays in HIV-1/2 Ag/Ab combination immunoassay positivity and indeterminate or negative results for supplemental HIV-1/HIV-2 Ab differentiation tests, concomitant routine HIV RNA testing can improve timely detection of breakthrough HIV infection.

ART can blunt viral load response. In one study, qualitative RNA testing was the most reliable detection method in cases with retrospective testing; however, the sensitivity of newer quantitative viral load tests is equal to available qualitative RNA tests. [Marzinke(a), et al. 2021].

HIV testing if exposure is suspected: For patients who present for PrEP initiation but have had a potential HIV exposure within the past 30 days, initial HIV testing may not detect early infection. Therefore, repeat HIV testing 1 month after initiation is recommended to rule out early HIV infection. For patients who report an interruption in PrEP during a time of sexual activity, an HIV-1/2 Ag/Ab combination immunoassay and HIV RNA test are recommended when reinitiating PrEP.

HIV testing if acute HIV is suspected: Vigilance for signs and symptoms of potential HIV seroconversion in individuals taking PrEP is crucial. If acute HIV is suspected, the clinician should perform an HIV-1/2 Ag/Ab combination immunoassay and a quantitative HIV RNA test [Chin, et al. 2013; Apoola, et al. 2002]. When testing for acute HIV infection is indicated, any use of a rapid HIV-1/2 Ag/Ab test should be followed with a laboratory-based HIV-1/2 Ag/Ab combination immunoassay. Detection of HIV RNA or Ag in the absence of serologic evidence of HIV should be considered a preliminary positive result (see guideline section Managing a Positive HIV Test Result).

For more detailed recommendations on testing for acute HIV, see the NYSDOH AI guidelines Diagnosis and Management of Acute HIV Infection and HIV Testing.

Routine Laboratory Testing

Renal function testing: One sign of tenofovir toxicity is the development of proteinuria. A baseline urinalysis helps to identify preexisting proteinuria before initiating PrEP. Periodic renal function monitoring is also important while a patient is taking TDF/FTC or TAF/FTC as PrEP. An elevated creatinine level should prompt an assessment for causes of renal dysfunction other than tenofovir, such as the use of nonsteroidal anti-inflammatory drugs, and an assessment for possible spurious elevation caused by the use of creatine supplements.

More frequent creatinine screening may be appropriate in individuals >40 years old because renal toxicity is more likely to occur in this population [Gandhi, et al. 2016]. More frequent screening may also be appropriate for patients with comorbidities, such as diabetes or hypertension, and patients taking concomitant nephrotoxic drugs that might increase the risk of renal dysfunction.

CAB is not known to cause renal dysfunction, but caution and increased monitoring for adverse effects is recommended when CrCl is <30 mL/min. Baseline testing and annual monitoring of renal function are recommended.

STI screening: Many patients who elect to initiate PrEP are at high risk of acquiring STIs, including syphilis and gonorrheal and chlamydial infections. Initiating PrEP care for individuals at risk for HIV provides an opportunity for routine STI monitoring and treatment. One modeling study demonstrated that increased PrEP engagement along with routine STI screening and treatment would lower STI rates through detection and treatment of asymptomatic STIs that might otherwise remain undiagnosed [Jenness, et al. 2017].

Data from New York State and other jurisdictions show high rates of STIs, a majority of which are asymptomatic, making an inquiry about symptoms insufficient, and supporting testing for syphilis and gonococcal and chlamydial infections at frequent intervals [Tang, et al. 2020; Golub, et al. 2016; Liu, et al. 2016]. Less frequent testing can be considered for individuals at lower risk of acquiring STIs. However, frequent testing leads to early diagnosis and treatment of asymptomatic STIs and can decrease the development of complicated infections, such as neurosyphilis or pelvic inflammatory disease, and decrease transmission to sex partners.

STI testing is recommended every 3 months for individuals taking oral PrEP. Individuals receiving CAB LA as PrEP require visits every 2 months; STI screening can be performed at each injection visit for those at highest risk or every 4 months for those with average risk. The frequency of STI screening in all patients on PrEP can be adjusted based on risk assessment and occur less often in those at low risk for STI acquisition.

Routine syphilis serologic testing should be performed for all patients taking PrEP, and all patients should be asked about anatomic sites of potential exposure and screened for gonococcal and chlamydial infections accordingly. Men who have sex with men (MSM) and transgender women have particularly high rates of extragenital STIs, and performing only urine-based screening misses a majority of infections [Pitasi, et al. 2019; Patton, et al. 2014]. Three-site testing (genital, pharyngeal, and rectal) for gonococcal and chlamydial infections should be the default testing plan for MSM and transgender women unless such testing is declined because of lack of exposure at a site. A recent study reported high rates of extragenital gonococcal and chlamydial infections in transgender men attending STI clinics [Pitasi, et al. 2019]; therefore, risk for extragenital STIs should be considered in this population as well.

Because nucleic acid amplification testing has much higher sensitivity than culture, it is preferred for the diagnosis of gonococcal or chlamydial infection. The U.S. Food and Drug Administration has approved diagnostic extragenital gonorrhea and chlamydia tests [FDA(b) 2019], making access to testing more readily available.

Vaginal swabs are preferred over urine-based testing for cervical infections because of their sensitivity. For urethral infections, urine testing is preferred because of comfort. For transgender women with a neovagina, data are lacking regarding optimal specimen type (neovaginal swab vs. urine-based testing). There are some reports of gonococcal infections detected via testing obtained from the neovagina [van der Sluis, et al. 2015]. Self-obtained swabs for vaginal, rectal, and pharyngeal specimen types have performed well in many studies and are preferred by many patients (see STI self-collection outside of a clinic setting in NYS Question & Answer) [Dize, et al. 2016; Lunny, et al. 2015; Workowski and Bolan 2015; Taylor, et al. 2013].

Annual HCV screening: An increased risk for HCV acquisition has been noted in MSM using PrEP [Price, et al. 2019; Hoornenborg(b), et al. 2017]. MSM with HIV [Fierer and Factor 2015; Bradshaw, et al. 2013; Fierer 2010] and to a lesser degree MSM without HIV [McFaul, et al. 2015] are at increased risk for acute HCV. A case-control study of MSM with HIV found that the presence of recent ulcerative STIs or risk behaviors, such as unprotected receptive anal intercourse, sharing of sex toys, unprotected fisting, injecting drugs, and sharing straws when snorting drugs, contributed to an increased risk of HCV acquisition [Vanhommerig, et al. 2015]. These may also be important risk factors in the general population. New elevations in liver enzymes can be a sign of acute HCV. Annual screening for HCV in MSM, transgender women, and individuals using injection drugs who are using PrEP is recommended, with more frequent screening considered for those at highest risk or with any elevations of liver function tests.

Pregnancy screening: In individuals of childbearing potential taking PrEP, routine assessment for the possibility of pregnancy and testing as appropriate decrease potential concerns associated with unplanned pregnancies. Individuals of childbearing potential who are using PrEP and wish to avoid pregnancy should be offered contraception. TDF/FTC as PrEP does not affect levels of hormonal contraceptives, and CAB LA does not affect levels of oral contraceptives and is not expected to affect levels of long-acting contraception.

Suspected Acute HIV

Vigilance for signs and symptoms of potential HIV seroconversion in patients receiving PrEP is crucial. TDF/FTC, TAF/FTC, or CAB LA as PrEP are not adequate treatments for acute or chronic HIV infection, and continued use in the presence of HIV may lead to the emergence of viral resistance to these drugs.

The mean time from HIV exposure to onset of symptoms is generally 2 to 4 weeks, with a range of 5 to 29 days; however, some patients are asymptomatic, and some have presented with symptoms up to 3 months after exposure [Apoola, et al. 2002]. This time course may be prolonged in patients who acquire HIV while on PrEP, and symptoms of acute HIV infection may be blunted by TDF/FTC, TAF/FTC, or CAB use. While evaluating patients for acute HIV, advise them to refrain from sexual activity or use condoms to minimize the risk of transmitting HIV to a partner without HIV.

For patients with symptoms consistent with acute HIV infection who have a nonreactive HIV test result but have a plasma HIV RNA level ≥200 copies/mL, a clinician can make a presumptive diagnosis of acute HIV, perform HIV genotype testing, obtain routine initial HIV laboratory tests, and recommend immediate initiation of ART.

For patients who have a nonreactive HIV test result but have an HIV RNA level <200 copies/mL, clinicians should repeat HIV RNA testing and repeat HIV diagnostic testing according to the standard HIV laboratory testing algorithm to exclude a false-positive test result versus a true-positive test result with a blunted viral response due to the presence of TDF/FTC, TAF/FTC, or CAB. Unless suspicion for acute HIV is low, initiate ART while a definitive diagnosis is sought.

Asymptomatic Patients With a Reactive HIV Screening Test Result

HIV acquisition in patients who are fully adherent to oral PrEP is rare. If a patient taking oral PrEP tests positive for HIV on a routine HIV-1/2 Ag/Ab combination immunoassay, determine if there has been any medication interruption or decreased adherence. A false-positive test result is more likely to occur when patients are not fully adherent to PrEP. There is an increased possibility of a true-positive test result if an individual reports gaps in adherence, medication access, or symptoms consistent with acute HIV in the period since their last HIV test. There are no commercially available tests of TDF concentrations to confirm longer-term adherence in someone with possible seroconversion on PrEP. Hair samples and dried blood spots are utilized as tests in research only. Because false-positive HIV-1/2 Ag/Ab combination immunoassay results do occur and there is a risk of HIV exposure if PrEP is discontinued, it is recommended that PrEP be continued. Clinicians should decide whether to continue PrEP or intensify to a fully suppressive ART regimen (see above) while awaiting confirmatory test results based on the degree of suspicion for a false-positive versus a true-positive HIV test result. Clinicians should perform supplemental diagnostic testing as soon as possible according to the standard HIV laboratory testing algorithm.

For asymptomatic patients with a positive HIV test result who are receiving CAB LA, assess for missed injections or adherence to the oral CAB during lead-in (if implemented). If PrEP has been interrupted, there is a much higher likelihood of a true-positive HIV test result. There were 4 breakthrough HIV infections with CAB LA despite on-time injections in the HPTN 083 study [Landovitz, et al. 2021], although there were no breakthrough infections with on-time injections in the HPTN 084 study [Delany-Moretlwe, et al. 2022]. Therefore, adherence to the CAB LA injection schedule does not guarantee protection, although breakthrough infections are uncommon. If a patient is nonadherent to either oral or injectable CAB, the clinician should prescribe a non-INSTI-based ART regimen, as discussed above, while awaiting confirmation of HIV and resistance test results. If a patient has been receiving injections on time, the possibility of a false-positive HIV test is higher, and the clinician can choose whether to await confirmation or prescribe a non-INSTI-based ART regimen pending test results.

If supplemental laboratory testing confirms HIV infection, the clinician should perform quantitative HIV RNA testing (if not already obtained) to measure viral load, order ART initiation laboratory testing, perform genotypic resistance testing, and initiate ART as in ART Selection For Patients Who Acquire HIV While on PrEP, below.

Ambiguous HIV Test Results

The use of TDF/FTC, TAF/FTC, or CAB LA as PrEP may alter viral load and immune response and cause ambiguous HIV test results when the current CDC/APHL HIV testing algorithm is followed [Zucker, et al. 2018; Hoornenborg(a), et al. 2017; Knox, et al. 2017; Markowitz, et al. 2017]. Viral load may be suppressed. An HIV-1/2 Ag/Ab combination immunoassay may be reactive, but supplemental testing (HIV-1/HIV-2 Ab differentiation, HIV RNA, or Western blot) may not consistently be reactive, or the time to reactivity may be delayed. In the HPTN 083 study of CAB LA as PrEP, in which there were 12 incident HIV infections, the use of HIV Ag/Ab testing alone led to a significant delay in detection of HIV infection, and retrospective analysis found ambiguous test results [Marzinke(a), et al. 2021].

In cases of ambiguous HIV test results in individuals taking PrEP, repeat HIV testing in a few days may resolve ambiguity if the initial results were due to early infection or technical issues.

If ambiguity persists, the options are to continue PrEP, intensify to a full HIV treatment regimen while waiting for additional testing to resolve the ambiguity, or discontinue PrEP and allow viral replication to occur and be measured if the patient does have HIV. However, discontinuing PrEP leaves an uninfected individual at risk. Delaying intensification risks loss of the theoretical virologic and immunologic benefits of early ART in an individual who does have HIV. Given the complexities of this issue, consultation with an experienced HIV care provider is recommended (see A Strategy for PrEP Clinicians to Manage Ambiguous HIV Test Results During Follow-Up Visits for a thorough review of this topic [Smith, et al. 2018]).

ART Selection For Patients Who Acquire HIV While on PrEP

Because HIV acquisition in individuals taking oral PrEP is most often due to nonadherence, the majority of infections are found to be wild-type virus. When resistance does occur, FTC-associated resistance due to the emergence of the M184V/I mutation is commonly found; tenofovir-associated resistance with the K65R mutation is rare [Girometti, et al. 2022; Mayer, et al. 2020; Lehman, et al. 2015]. Among individuals receiving CAB LA in the HPTN 083 study, INSTI-associated mutations were observed in 1 individual with baseline HIV infection and 4 individuals with incident HIV infection [Landovitz, et al. 2021]. No participants in the HPTN 084 study developed INSTI resistance [Marzinke(b), et al. 2021]. There are no definitive protocols for specific antiretroviral agents to use in the case of suspected seroconversion in individuals taking PrEP. However, for patients taking oral PrEP, given the rarity of tenofovir-associated mutations during PrEP use, a reasonable option would be to continue TDF/FTC or TAF/FTC and add a third agent with a high resistance barrier, such as DRV/COBI, DTG, or BIC (available as TAF/FTC/BIC) while awaiting HIV confirmation and resistance test results. For patients receiving CAB LA, initiation of a non-INSTI-based ART regimen is recommended while awaiting confirmation of HIV infection and resistance test results. If no INSTI resistance is found, the patient can be switched to an INSTI-based ART regimen if desired. For more information, see the NYSDOH AI guidelines Rapid ART Initiation and Selecting an Initial ART Regimen.